कृपया अन्य खोज का प्रयास करें
Nippon Chemiphar Co., Ltd., together with its subsidiaries, engages in the manufacture, sale, import, and export of ethical pharmaceuticals and diagnostic agents in Japan and internationally. the company offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. It also develops NC-2400, a PPAR-delta agonist currently under phase 1 development; NC-2500, a XOR inhibitor for the treatment of hyperuricemia/gout currently under phase 1 development; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain currently under phase 1 development. In addition, the company develops NC-2700, a URAT1 inhibitor for hyperuricemia, guot currently under preclinical development; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety currently under Phase 1 development; DFP-17729, a cancer microenvironment improving agent far pancreatic cancer currently under phase 2 development; and DE-P-14323, an anti-cancer agent for non-small cell lung cancer currently under phase 2 development. Further, it is involved in the development of Soleton, an analgesic and anti-inflammatory drug; and Calvan, a blocker for huntington's disease currently under phase 2 development. Additionally, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various types of creams. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was incorporated in 1950 and is headquartered in Tokyo, Japan.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Kazushiro Yamaguchi | 63 | 1987 | Chairman, CEO & President |
Masanori Kutsuwada | 67 | 2009 | Senior Managing Corporate Officer & Director |
Tomio Yamakawa | 69 | 2012 | Director & Senior Managing Corporate Officer |
Masahide Yasumoto | 56 | 2012 | Ops., Info. Sys. Dept., Pub. Rel., Lab. Drugs, Corp. Plan., Mgr., Managing Corp. Offr.& Dir. |
Naoshige Shindou | 75 | 2008 | Outside Audit & Supervisory Board Member |
Masaki Yoshino | 63 | 2019 | Independent Outside Director |
Yuji Harada | 72 | 2017 | Independent Outside Director |
Kouki Hayamizu | 61 | 2019 | Corporate Officer & Director |
Naoko Omukai | 49 | 2023 | Outside Independent Director |
Sakaru Makino | 63 | 2020 | Full Time Audit & Supervisory Board Member |
Rumi Yamaguchi | - | 2022 | Outside Audit & Supervisory Board Member |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है